Results per Page:
Skin in the game: Changing the story of Merkel cell carcinoma
How the Nghiem Lab and its supporters are improving outcomes for patients with a rare cancer
El descubrimiento de un gen supresor de tumores oculto en el genoma del virus causante del carcinoma de células de Merkel
Del Laboratorio Galloway, División de Biología Humana
Discovery of a hidden tumor suppressor in the genome of the virus that causes Merkel cell carcinoma
From the Galloway Lab, Human Biology Division
New biomarker could one day help tailor immunotherapy for Merkel cell carcinoma
Helps explain why only certain MCC patients respond to immune checkpoint inhibitors, could point toward new strategies to improve treatment responses
Rethinking immunotherapy dosing frequency for better cost, time, and life savings!
From the Bhatia group, Clinical Research Division
Reducing frequency of immunotherapy dosing could save money and time, keep patients on therapy longer
Study of immune checkpoint inhibitor dosing in patients with advanced skin cancers could help guide long-term treatment plans
Macrophages predict response to immunotherapy in Merkel cell carcinoma
From the Nghiem lab, Fred Hutch Clinical Research Division & UW Dermatology
Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow
Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald
Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy
Cancer biologist contributed basic and translational insights that made the cancer-preventive HPV vaccine possible
Dr. Martin 'Mac' Cheever, cancer immunotherapy expert, receives distinguished service award
Honor recognizes his work establishing Cancer Immunotherapy Trials Network
$12M NIH grant to study rare, aggressive skin cancer
Fred Hutch, UW researchers hope to improve immunotherapies for people with Merkel cell carcinoma
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Seattle team pivotal to FDA OK on drug for rare skin cancer
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Immune booster may awaken body’s defenses against skin cancer
First-in-human pilot of experimental immunotherapy in Merkel cell carcinoma
Molecular mechanisms of late cancer relapse
from the Chapuis lab, Clinical Research Division
Revealing a new way that cancer can evade immunotherapy — and, maybe, how to stop it
How a new technology solved a mystery and honors one man’s legacy
Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse
A Nature Communications report explains why some Merkel cell carcinoma patients treated with immunotherapy see their cancers shrink at first but then come back.